I-SPY 2: immunotherapy biomarkers in early breast cancer

I-SPY2.2: emerging biomarkers in breast cancerПодробнее

I-SPY 2: advancing outcomes high-risk breast cancer through adapting therapiesПодробнее

Cancer Early Detection & Interception Panel Part 4: I-SPY 2 - Breast Cancer TreatmentПодробнее

Predictive biomarkers in breast cancerПодробнее

Using single cell technologies to identify biomarkers for breast cancer patient outcomesПодробнее

The role of biomarkers in guiding treatment for early-stage breast cancerПодробнее

Precision Medicine In Early Stage Breast Cancer: The I-SPY 2 Experience: PGx Conference 2018Подробнее

Prognostic biomarkers of immunotherapy efficacy in breast cancerПодробнее

I-Spy Trial: Precision medicine and Biomarket Discovery for Early Stage Breast Cancer, by Julia WulfПодробнее

Immunotherapy biomarkers in neoadjuvant breast cancerПодробнее

Dr. Esserman Discusses the I-SPY 2 Trial in Breast CancerПодробнее

Elucidating immunotherapy biomarkers for breast cancerПодробнее

Innovative biomarker approaches in breast cancer therapyПодробнее

NBC 4 Report: I-SPY 2 Clinical TrialПодробнее

Dr. Esserman on the Elements of the I-SPY 2 Trial in Breast CancerПодробнее

Paula Pohlmann - Precision medicine in the treatment of patients with breast cancer: I-SPY trialsПодробнее

Meredith Buxton Discusses the I-SPY 2 TrialПодробнее

FOXC1 as a novel prognostic biomarker in immune checkpoint inhibitor therapyПодробнее

Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response AssessmentПодробнее